Susanna High named CEO of Paragon

Paragon Therapeutics Inc. named Susanna High CEO. High was COO of Dyne Therapeutics Inc. (NASDAQ:DYN), before which she worked at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for almost a decade. Backed by Fairmount Funds, Paragon incubates companies focused on developing biologics; its spinout Crescent Biopharma Inc. announced last month it is going public via a reverse merger with GlycoMimetics Inc. (NASDAQ:GLYC). 

Lee Patterson became CEO of Metrion Biosciences Ltd., a preclinical contract research organization. Patterson, who succeeds Andrew Southan, was CEO of Charnwood Discovery Ltd., which was acquired last month by Concept Life Sciences...